Boehringer Ingelheim Vetmedica (BIV), the animal health division of the privately held German multinational pharmaceutical company Boehringer Ingelheim, has reported a 30% growth in 2009 revenues, largely driven by swine vaccine sales. The company had 2009 revenues of €610 million ($819.4m), ...
Please Login to read the full article.
